-
The new domestic hypoglycemic medicine is hot! Over 50 Class 1 new drugs hit Hengrui and other 3 major tracks
Time of Update: 2021-12-07
Including compound preparations, there are currently 9 domestic GLP-1 receptor agonists approved for marketing (2 are domestically produced Class 1 new drugs).
In addition to the two domestically-made GLP-1 receptor agonists that have been approved for marketing, according to incomplete statistics, there are currently 17 domestically-made Class 1 new drugs in phase I and above .
-
Announcement of the clinical data of the new conjugation drug VDC!
Time of Update: 2021-12-07
AU-011's dual mechanism of killing tumors (Source: Aura official website)The Phase Ib/II clinical trial of AU-011 evaluated the safety and effectiveness of IVT administration in the treatment of IL and CM .
-
The State Food and Drug Administration cancels the registration certificates of 8 varieties of drugs including Xiaoerfenaminokamin granules
Time of Update: 2021-12-07
After evaluation, the State Drug Administration has decided to stop the production, sales and use of the above-mentioned eight varieties in China and cancel the drug registration certificate from now on .
-
CAR-T therapy has huge market development space, which is attracting domestic pharmaceutical companies to actively explore
Time of Update: 2021-12-07
It is worth noting that, facing the considerable market prospects, pharmaceutical companies have begun to accelerate their exploration in the field of CAR-T cell therapy .
But in fact, domestic pharmaceutical companies have been actively deploying CAR-T cell therapy drugs in recent years .
-
RedHill announces that related trials have completed randomization of patients
Time of Update: 2021-12-07
Part A of the Phase 2/3 study for patients with new coronary pneumonia who have developed symptoms but do not require hospitalization by oral administration of RHB-107 (upamostat) once a day has compl
-
Centralized procurement to normalize a batch of pharmaceutical companies out
Time of Update: 2021-12-07
Centralized procurement is normalized, the cancellation of drug approvals by pharmaceutical companies accelerates, and the number of companies continues to declineCentralized procurement is one of the major policies that have affected the pharmaceutical industry in the past two years.
-
CGRP migraine competition intensifies Lundbeck Pharma lays off 300 employees
Time of Update: 2021-12-07
CompilationFan DongdongIn February last year, with the approval of the US FDA, Lundbeck Vyepti (a CGRP inhibitor infusion) directly entered the pandemic and migraine market, which is now flooded with injection and oral options from large pharmaceutical companies .
-
From November 15th to November 16th, a collection of important announcements in the pharmaceutical industry
Time of Update: 2021-12-07
On November 15th, Sinopharm Hyundai issued an announcement that the company's holding subsidiary Sinopharm Yixin Received the “Approval Notice of Drug Supplement Application” for Octreotide Acetate Injection approved and issued by the National Food and Drug Administration, and approved the drug to pass the generic drug quality and efficacy consistency evaluation .
-
Hutchison Medicine's CSF-1R inhibitor HMPL-653 capsule was approved for clinical use in China
Time of Update: 2021-12-07
ArticleMedicine GuanlanAccording to the latest announcement from the Center for Drug Evaluation (CDE) of the National Food and Drug Administration of China, Hutchison Medicine’s HMPL-653 capsule has just received an implied clinical trial approval and plans to develop treatments for advanced malignant solid tumors and giant cell tumors of tendon sheaths (TGCT) .
-
The State Administration of Traditional Chinese Medicine issued a document!
Time of Update: 2021-12-07
Novice on the road, new regulations for Chinese medicine formula granules01 Clear sales location01 Clear sales locationOn November 16, the State Administration of Traditional Chinese Medicine issued the "Notice on Regulating the Clinical Use of TCM Formula Granules in Medical Institutions" (hereinafter referred to as "standards").
-
Advanced Sterilization Products leader raises medical infection prevention standards in Asia
Time of Update: 2021-12-07
Nilesh Shah, Vice President, General Manager and Global Business Leader of Advanced Sterilization Products (ASP)After successfully responsible for the sale of ASP from Johnson & Johnson to Fortive (as the parent company) in 2019, Nilesh expanded ASP to emerging markets in Asia, providing infection prevention technologies and workflow solutions for healthcare facilities to improve efficiency and productivity .
-
Gan Lai announced that the farnesol X receptor agonist ASC42 for the treatment of primary biliary cholangitis Phase II and III clinical trial protocol was approved by the China National Food and Drug Administration
Time of Update: 2021-12-07
Based on the Phase II and Phase III clinical trial protocol of ASC42 for the treatment of PBC approved by the National Food and Drug Administration of China, Gan Lai will conduct phase II clinical trials in 100 patients with insufficient or intolerance to ursodeoxycholic acid (UDCA).
-
Industry: starting next year, the golden age of the pharmaceutical sector will restart
Time of Update: 2021-12-07
China Merchants Fund believes that under the situation of a high base last year, the performance of pharmaceutical companies in the third quarter has clearly differentiated, and it is expected that the trend of differentiation will continue in the market outlook .
-
The procurement peak period for vaccine production equipment has passed, where should pharmaceutical machinery companies go?
Time of Update: 2021-12-07
Since 2020, many pharmaceutical machinery companies have benefited from the increase in vaccine-related business and achieved a significant increase in orders for vaccine production equipment, which has contributed to the growth of performance to a certain extent .
-
Ruike Biotechnology obtained the New Crown Vaccine "Drug Production License" issued by the Jiangsu Provincial Food and Drug Administration
Time of Update: 2021-12-07
The new crown vaccine and adjuvant production base established by Ruike Biotech in Taizhou, Jiangsu Province is constructed in accordance with the current international GMP standards.
-
The world’s first solid tumor CAR-T to obtain PRIME qualification, Keji Pharmaceutical’s CT041 was granted priority medicine (PRIME) qualification by the European Medicines Agency (EMA)
Time of Update: 2021-12-07
So far, Keji Pharmaceuticals has become the only company in the world that has two CAR-T products included in the PRIME plan .
Keji Pharmaceutical's mission is to'cure tumors', and through continuous technological innovation, we will strive to develop better therapeutic drugs for cancer patients around the world .
-
The two pharmaceutical companies have reached a major cooperation, the tens of billions of long-acting growth hormone market may face changes
Time of Update: 2021-12-07
On November 11, Jichuan Pharmaceutical issued an announcement, announcing that it had reached a strategic cooperation in product development, production and commercialization with Tianjing Bio on long-acting recombinant human growth hormone (Yitan) .
-
AZ over $1 billion injections, Hausen will be approved for Huiyu's new entry
Time of Update: 2021-12-07
Figure 3: Enterprise competitive landscape of 2021H1 Fulvestrant injection Source: Mi Nei. com, China's public medical institutions terminal competition pattern CP Tianqing Pharmaceutical Group submitted 4 types of generic listing applications in 2019, and was approved for the first imitation + first review in August 2020.
-
110 medical device products have been approved and registered by the State Food and Drug Administration
Time of Update: 2021-12-07
On November 15, the State Drug Administration issued an announcement stating that in October 2021, the State Drug Administration approved and registered 110 medical device products .
-
AstraZeneca structure adjustment!
Time of Update: 2021-12-07
On November 15th, AstraZeneca China officially announced to employees that some of the business structure has been adjusted, and the main changes are in the two core sectors: Jixian Business and Cardiovascular As for the metabolism and kidney business, the following two specific adjustments have been made:Division of Hexian Business: Hexian Oncology Business was merged into Oncology Division, and non-oncology business was independent, becoming Jixian Chronic Disease Business Department .
